Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00238/full |
| _version_ | 1818320393152233472 |
|---|---|
| author | Barbara eMelosky Vera eHirsh |
| author_facet | Barbara eMelosky Vera eHirsh |
| author_sort | Barbara eMelosky |
| collection | DOAJ |
| description | Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-type NSCLC. As promising as TKIs are in helping patients avoid some of the side effects of traditional cytotoxic chemotherapy, they do come with a variety of side effects.This article will describe the most common adverse events associated with the epidermal EGFR family of TKIs including diarrhea, rash, mucositis, and paronychia. The objective of this paper is to provide simple guidelines to assist oncologists in managing these common toxicities. As patient survival is often directly correlated with successful therapeutic drug delivery, the management of TKI- induced adverse events ensures proper treatment and may avoid discontinuation or reduction of the therapeutic. |
| first_indexed | 2024-12-13T10:24:17Z |
| format | Article |
| id | doaj.art-3d1b2a1cc35045c3a754a9d75c29ba8f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T10:24:17Z |
| publishDate | 2014-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3d1b2a1cc35045c3a754a9d75c29ba8f2022-12-21T23:51:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-09-01410.3389/fonc.2014.00238100701Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIsBarbara eMelosky0Vera eHirsh1British Columbia Cancer Agency (BCCA) - Vancouver CentreMcGill University Health Centre - Royal Victoria HospitalTyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-type NSCLC. As promising as TKIs are in helping patients avoid some of the side effects of traditional cytotoxic chemotherapy, they do come with a variety of side effects.This article will describe the most common adverse events associated with the epidermal EGFR family of TKIs including diarrhea, rash, mucositis, and paronychia. The objective of this paper is to provide simple guidelines to assist oncologists in managing these common toxicities. As patient survival is often directly correlated with successful therapeutic drug delivery, the management of TKI- induced adverse events ensures proper treatment and may avoid discontinuation or reduction of the therapeutic.http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00238/fullDiarrheaParonychiaEGFRTyrosine kinase inhibitor (TKI)Adverse event managementRash |
| spellingShingle | Barbara eMelosky Vera eHirsh Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs Frontiers in Oncology Diarrhea Paronychia EGFR Tyrosine kinase inhibitor (TKI) Adverse event management Rash |
| title | Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs |
| title_full | Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs |
| title_fullStr | Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs |
| title_full_unstemmed | Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs |
| title_short | Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs |
| title_sort | management of toxicities in metastatic nsclc related to anti lung cancer therapies with egfr tkis |
| topic | Diarrhea Paronychia EGFR Tyrosine kinase inhibitor (TKI) Adverse event management Rash |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00238/full |
| work_keys_str_mv | AT barbaraemelosky managementoftoxicitiesinmetastaticnsclcrelatedtoantilungcancertherapieswithegfrtkis AT veraehirsh managementoftoxicitiesinmetastaticnsclcrelatedtoantilungcancertherapieswithegfrtkis |